Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target

Core Viewpoint - Iovance Biotherapeutics Inc. is experiencing significant investor interest, highlighted by a recent price target increase from UBS and a bullish rating from Wells Fargo, indicating potential growth opportunities in the biopharmaceutical sector [1][2]. Group 1: Stock Performance - Iovance reached a new 52-week high of $5.34 during intra-day trading, closing at $5.13, which represents a 12.01% increase [1]. - UBS raised its price target for Iovance from $2 to $4, maintaining a "neutral" stance on the stock [1]. - Wells Fargo reaffirmed a more optimistic price target of $14 with a "buy" recommendation [2]. Group 2: Financial Performance - Iovance reported a net loss of $390.98 million for the last year, which is a 5% increase from a loss of $372 million in 2024 [3]. - Total revenues for the company increased by 60.6% year-on-year, reaching $263.5 million compared to $164.07 million [3]. - In the fourth quarter, the net loss narrowed by 8% to $71.9 million from $78.5 million in the same period the previous year, while revenues grew by 17.6% to $86.7 million from $73.69 million [3]. Group 3: Upcoming Events - Investors are expected to closely monitor business updates from Iovance during its participation in Barclays' 28th Annual Global Healthcare Conference on March 11 [2].